Rita Cagigal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rita Cagigal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Amélia Mendes
Neurology Deparment, Unidade Local de Saúde de Gaia e Espinho, Vila Nova de Gaia, Porto, Portugal
1 shared publication- Ana Luísa Rocha
Unidade Local de Saúde de Vila Nova de Gaia/Espinho, Departamento de Neurologia, Vila Nova de Gaia, Portugal
1 shared publication Andrea Garcia‐Ortega
Epilepsy and Functional Neurological Disorders Unit Neuralma Institute, Blua Sanitas Valdebebas University Hospital Madrid Spain
1 shared publicationAndré Miranda
Neurorradiology Functional Unit, Imagiology Department, Unidade Local de Saúde de Gaia e Espinho, Vila Nova de Gaia, Porto, Portugal
1 shared publication- Bárbara Martins
Serviço de Neurologia Hospital Universitário São João Porto Portugal
1 shared publication - Carla Morgado
Neurology Department Unidade Local de Saúde de Braga Braga Portugal
1 shared publication
Latest Publications
- 7 September 2026
- Published by Wiley in Epileptic Disorders
Functional (dissociative) seizures in PCDH19 ‐clustering epilepsy: Clinical characteristics and diagnostic challenges
Objective: Functional (dissociative) seizures (FDS) are increasingly recognized among individuals with epilepsy, intellectual disability (ID), and psychiatric disorders, but their occurrence in PCDH19‐clustering epilepsy (CE) has not been systematically described. We aimed to characterize the clinical features, diagnostic pathways, and management of FDS in individuals with genetically confirmed PCDH19‐CE. Methods: We conducted a multicenter retrospective study across six tertiary European Epilepsy Centers. Individuals with genetically confirmed PCDH19‐CE and a diagnosis of FDS according to the International League Against Epilepsy (ILAE) criteria were included. Demographic, clinical, neuropsychiatric, neurophysiological, neuroimaging, and treatment‐related data were collected from medical records. Results: Among 27 individuals with genetically confirmed PCDH19‐CE, eight (29.6%) experienced FDS. The median age at FDS onset was 16 years. Most affected individuals had some degree of ID, and nearly all exhibited psychiatric comorbidities, particularly behavioral dysregulation and autism spectrum disorder. Six patients were initially misdiagnosed with epileptic seizures, resulting in unnecessary antiseizure medication (ASM) escalation and hospitalizations. Following FDS diagnosis, ASM reduction or modification was undertaken in three patients. Multidisciplinary management involving psychiatry, psychology, and occupational therapy was implemented in most cases, and all treated individuals demonstrated clinical improvement. Significance: FDS may constitute an important comorbidity in individuals with PCDH19‐CE, particularly during adolescence and adulthood. Early recognition of FDS may prevent unnecessary diagnostic and therapeutic interventions, reduce inappropriate ASM escalation, and improve patient outcomes through timely multidisciplinary care.
- 7 September 2026
- Published by Wiley in Epileptic Disorders
Functional (dissociative) seizures in PCDH19 ‐clustering epilepsy: Clinical characteristics and diagnostic challenges
Objective: Functional (dissociative) seizures (FDS) are increasingly recognized among individuals with epilepsy, intellectual disability (ID), and psychiatric disorders, but their occurrence in PCDH19‐clustering epilepsy (CE) has not been systematically described. We aimed to characterize the clinical features, diagnostic pathways, and management of FDS in individuals with genetically confirmed PCDH19‐CE. Methods: We conducted a multicenter retrospective study across six tertiary European Epilepsy Centers. Individuals with genetically confirmed PCDH19‐CE and a diagnosis of FDS according to the International League Against Epilepsy (ILAE) criteria were included. Demographic, clinical, neuropsychiatric, neurophysiological, neuroimaging, and treatment‐related data were collected from medical records. Results: Among 27 individuals with genetically confirmed PCDH19‐CE, eight (29.6%) experienced FDS. The median age at FDS onset was 16 years. Most affected individuals had some degree of ID, and nearly all exhibited psychiatric comorbidities, particularly behavioral dysregulation and autism spectrum disorder. Six patients were initially misdiagnosed with epileptic seizures, resulting in unnecessary antiseizure medication (ASM) escalation and hospitalizations. Following FDS diagnosis, ASM reduction or modification was undertaken in three patients. Multidisciplinary management involving psychiatry, psychology, and occupational therapy was implemented in most cases, and all treated individuals demonstrated clinical improvement. Significance: FDS may constitute an important comorbidity in individuals with PCDH19‐CE, particularly during adolescence and adulthood. Early recognition of FDS may prevent unnecessary diagnostic and therapeutic interventions, reduce inappropriate ASM escalation, and improve patient outcomes through timely multidisciplinary care.
- 24 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5) , 456
Real-world challenges in primary central nervous system lymphoma: a case series
- 24 April 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (5) , 456
Real-world challenges in primary central nervous system lymphoma: a case series
- Open Access
- 28 February 2026
- Published by The Korean Headache Society in Headache and Pain Research
- Vol. 27 (1) , 43-51
The Impact of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Sleep Quality and Daytime Sleepiness in Migraine Patients: A Multicenter Study
Purpose: This study aimed to determine whether patients with migraine experience improvements in self-reported sleep quality and daytime sleepiness after starting monoclonal antibody (mAb) therapy targeting the calcitonin gene-related peptide (CGRP) or its receptor, and to explore the association between treatment efficacy and improvements in sleep quality.Methods: This prospective, multicenter, observational, longitudinal study was conducted across 12 headache centers. Adults with episodic or chronic migraine who began anti-CGRP mAb therapy were assessed at baseline, 3 months, and 6 months. Sleep quality and daytime sleepiness were evaluated using the Portuguese version of the Pittsburgh Sleep Quality Index (PSQI-PT) and the Portuguese version of the Epworth Sleepiness Scale (ESS-PT), respectively. Results: Of 118 enrolled patients, 109 completed the study (86.4% female; mean age, 43.6 years). A significant improvement in sleep quality was observed, with median PSQI-PT scores decreasing from 9 at baseline to 6 at 6 months (p<0.001). Daytime sleepiness also improved, with median ESS-PT scores decreasing from 7 to 6 (p=0.04). Migraine frequency decreased significantly, from a median of 13 to 4 monthly migraine days (p<0.001). Greater migraine improvement was independently associated with greater PSQI-PT improvement (p<0.001), whereas changes in ESS-PT were not correlated with treatment efficacy.Conclusion: Anti-CGRP mAb therapy was associated with significant improvements in sleep quality, likely mediated through migraine relief. Changes in ESS-PT were not correlated with treatment efficacy, suggesting a possible interaction between migraine mechanisms and CGRP-mediated sleep–wake regulation. Future research should focus on clarifying the mechanisms underlying these associations.
- 28 February 2026
- Published by The Korean Headache Society in Headache and Pain Research
- Vol. 27 (1) , 43-51
Open AccessThe Impact of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Sleep Quality and Daytime Sleepiness in Migraine Patients: A Multicenter Study
Purpose: This study aimed to determine whether patients with migraine experience improvements in self-reported sleep quality and daytime sleepiness after starting monoclonal antibody (mAb) therapy targeting the calcitonin gene-related peptide (CGRP) or its receptor, and to explore the association between treatment efficacy and improvements in sleep quality.Methods: This prospective, multicenter, observational, longitudinal study was conducted across 12 headache centers. Adults with episodic or chronic migraine who began anti-CGRP mAb therapy were assessed at baseline, 3 months, and 6 months. Sleep quality and daytime sleepiness were evaluated using the Portuguese version of the Pittsburgh Sleep Quality Index (PSQI-PT) and the Portuguese version of the Epworth Sleepiness Scale (ESS-PT), respectively. Results: Of 118 enrolled patients, 109 completed the study (86.4% female; mean age, 43.6 years). A significant improvement in sleep quality was observed, with median PSQI-PT scores decreasing from 9 at baseline to 6 at 6 months (p<0.001). Daytime sleepiness also improved, with median ESS-PT scores decreasing from 7 to 6 (p=0.04). Migraine frequency decreased significantly, from a median of 13 to 4 monthly migraine days (p<0.001). Greater migraine improvement was independently associated with greater PSQI-PT improvement (p<0.001), whereas changes in ESS-PT were not correlated with treatment efficacy.Conclusion: Anti-CGRP mAb therapy was associated with significant improvements in sleep quality, likely mediated through migraine relief. Changes in ESS-PT were not correlated with treatment efficacy, suggesting a possible interaction between migraine mechanisms and CGRP-mediated sleep–wake regulation. Future research should focus on clarifying the mechanisms underlying these associations.